ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38 Positive Hematologic Malignancies

Time: 3:15 pm
day: Day One


  • ISB 1442 represents a novel approach for the treatment of CD38+ tumors by cotargeting CD38 and CD47 with a 2+1 biparatopic bispecific antibody format with Fc engineering enhancing Fc effector functions
  • ISB 1442 shows higher potency relative to daratumumab in CD38high/low tumor models as measured by multiple antibody-dependent mechanisms of action in vitro and in vivo
  • ISB 1442 shows low on-target off-tumor binding and no RBC depletion compared to anti-CD47 mAb (5F9), potentially resulting in a better therapeutic index than anti-CD47 mAbs